About XinThera
XinThera is a company based in San Diego (United States) founded in 2021 by Qing Dong, Stephen Kaldor, and Gene Hung was acquired by Gilead in May 2023. XinThera has raised $50 million across 2 funding rounds from investors including Gilead, Orbimed and Foresite Capital. The company has 13 employees as of December 31, 2021. XinThera operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 13 as on 31 Dec, 2021
- Founders Qing Dong, Stephen Kaldor, Gene Hung
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Xinthera, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of XinThera
Unlock access to complete
Funding Insights of XinThera
XinThera has successfully raised a total of $50M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in XinThera
XinThera has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Orbimed and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
It serves as a ttm capital.
|
Locked | Locked | Locked |
Investor details for XinThera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by XinThera
Investment portfolio details for XinThera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - XinThera
Detailed financials for XinThera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xinthera Comparisons
Peer comparison for XinThera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of XinThera
XinThera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of XinThera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xinthera
Complete news archive for XinThera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XinThera
XinThera was founded in 2021.
XinThera is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
XinThera is a funded company, having raised a total of $50M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at XinThera is 13.
XinThera was founded in 2021 in San Diego, United States, by co-founders Qing Dong, Stephen Kaldor, and Gene Hung. Small-molecule therapeutics targeting immuno-oncology diseases are developed by the company within the biotechnology sector. Operations focus on advancing treatments for related conditions, with activities centered in the United States. The domain xinthera.com is maintained for company information.
XinThera's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
XinThera has 4 investors. Key investors include Gilead, Orbimed, Foresite Capital, and TTM Capital.